These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11074477)

  • 1. Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-alpha therapy.
    Radecke K; Protzer U; Trippler M; Meyer Zum Büschenfelde KH; Gerken G
    J Med Virol; 2000 Dec; 62(4):479-86. PubMed ID: 11074477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBV core region variability: effect of antiviral treatments on main epitopic regions.
    Homs M; Jardi R; Buti M; Schaper M; Tabernero D; Fernandez-Fernandez P; Quer J; Esteban R; Rodriguez-Frias F
    Antivir Ther; 2011; 16(1):37-49. PubMed ID: 21311107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing.
    Homs M; Buti M; Tabernero D; Quer J; Sanchez A; Corral N; Esteban R; Rodriguez-Frias F
    World J Gastroenterol; 2012 Nov; 18(42):6096-105. PubMed ID: 23155338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic variations in precore and cytotoxic T lymphocyte regions in chronic hepatitis B in relationship to interferon responsiveness.
    Shindo M; Okuno T
    Liver; 2000 Apr; 20(2):136-42. PubMed ID: 10847482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
    Günther S; Paulij W; Meisel H; Will H
    Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Zhang Y; Wu Y; Deng M; Xu D; Li X; Xu Z; Hu J; Zhang H; Liu K; Zhao Y; Gao F; Bi S; Gao GF; Zhao J; Liu WJ; Meng S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity.
    Torre F; Cramp M; Owsianka A; Dornan E; Marsden H; Carman W; Williams R; Naoumov NV
    J Med Virol; 2004 Mar; 72(3):370-6. PubMed ID: 14748060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B.
    Alexopoulou A; Owsianka AM; Kafiri G; Dourakis SP; Carman WF; Hadziyannis SJ
    J Hepatol; 1998 Sep; 29(3):345-51. PubMed ID: 9764979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatitis B before and after interferon treatment.
    Cabrerizo M; Bartolomé J; Otero M; Ruiz-Moreno M; Carreño V
    J Med Virol; 1999 Jul; 58(3):208-14. PubMed ID: 10447414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation--an insight from human immunodeficiency virus/hepatitis B virus coinfection.
    Mondal RK; Khatun M; Ghosh S; Banerjee P; Datta S; Sarkar S; Saha B; Santra A; Banerjee S; Chowdhury A; Datta S
    Clin Microbiol Infect; 2015 Jul; 21(7):710.e11-20. PubMed ID: 25882358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment.
    Zampino R; Marrone A; Cirillo G; del Giudice EM; Utili R; Karayiannis P; Liang TJ; Ruggiero G
    J Viral Hepat; 2002 May; 9(3):183-8. PubMed ID: 12010505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in Core Gene Region of Hepatitis B Virus in Patients with Chronic Hepatitis B.
    Ciftci S; Keskin F; Abaci N; Akyuz F; Cakiris A; Badur S; Kaymakoglu S; Ustek D
    Clin Lab; 2018 Mar; 64(3):303-310. PubMed ID: 29739114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
    Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
    J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC; Kim HJ; Do JH; Park SM
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response.
    Peng Y; Li Y; Hou J; Sun J; Su M; Li Y; Xiang K; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2017 Apr; 49():116-121. PubMed ID: 28088502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values.
    Alexopoulou A; Baltayiannis G; Eroglu C; Nastos T; Dourakis SP; Archimandritis AJ; Karayiannis P
    J Med Virol; 2009 Jan; 81(1):34-41. PubMed ID: 19031457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.